Skip to main content
USNA logo

USNA · Usana Health Sciences Inc

Track USNA — free
$14.14 -0.20 (-1.39%) At close · Sep 18
Market Cap
$277.52M
Shares
18.48M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.14 Open$14.30 Day$14.02–14.49 52W close$12.86–30.84 Avg vol 30d229K Short int646K · 3.5% float · 3.1d Short vol48% Last earningsAug 5, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Oct 29, 2026 Est · unconfirmed · in 6 wks
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$913.36M
Trailing 12 months
Net income (TTM)
−$22.16M
Trailing 12 months
Revenue growth YoY
-5.3%
Year over year
Operating margin
-0.1%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
5.7%
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$168.56M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
-0.3%
Year over year · fewer shares
Price change (1Y)
-54.2%
Trailing year
Short interest
3.5%
Latest settlement · 3.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −17%
below
RSI (14) 39
neutral
MACD trend Positive
52-week position 7%
near low
Momentum
relative strength
Weak
1-month return +7%
trailing
6-month return −16%
trailing
YTD return −28%
this year
Relative strength −37%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.49% of float · ▼ -14.6% MoM · 3.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
137 holders — mid 3-yr range
Squeeze score 43
elevated · 0–100
Fundamentals
Strong
Revenue growth −11%
Y/Y
Gross margin 68%
expanding
EPS growth −74%
Y/Y
Free cash flow $8.5M
Buyback $34.0M
remaining
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −58%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 4, 2026
Fiscal Year 2026
Hiya net sales Initiated $125M
Rise Wellness net sales Initiated $35M
Consolidated net sales Initiated $910M
prior FY $925.26M midpoint −1.6% Y/Y
Diluted EPS Initiated $-0.61
prior FY $0.58 midpoint −205.2% Y/Y
Adjusted diluted EPS Initiated $0.76
Adjusted EBITDA Initiated $87M
fiscal year 2026
Consolidated income taxes Initiated $30M
Prior guidance period ended · from the 8-K filed Apr 30, 2024
Consolidated Net Sales · Fiscal Year 2024 $850M – $920M
Operating margin · Fiscal Year 2024 8% – 9%
Annual effective tax rate · Fiscal Year 2024 38% – 40%
Guided vs delivered · last 1 settled
Consolidated Net Sales Fiscal Year 2024
guided $850M – $920M
$854.5M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
39 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.49% of float · ▼ -14.6% MoM · 3.1 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
137 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $13 Now $14 · 7% Range high $31
vs 200-day avg -25% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
USNA
Usana Health Sciences Inc
this stock
$277.52M -28.0% -10.8% 3.5%
JBS
Jbs N.V.
$39.34B -17.1% 1.2%
KHC
Kraft Heinz Co
$28.97B +0.7% -0.1% 8.3%
GIS
General Mills Inc
$19.57B -21.9% +4.1% 8.6%
SJM
J M SMUCKER Co
$13.13B +25.7% +3.7% 4.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
137
% held
61.8%
Net QoQ
+1.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
188
View
Short & Settlement
Short Interest Falling
Shares short
645.7K
Days to cover
3.1d
Change
-110.3K sh
View
Short Volume
Short vol %
48%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
506
Value
$6.9K
As of
Aug 24, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$925.3M
Net income (FY)
$10.8M
EPS diluted
$0.58
View
Buybacks
Authorized
$150.0M
Remaining
$34.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 13, 2026
This year
11
View
Proposed Sales
Value
$97.3K
Shares
5.0K
Filed
Jun 16, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
USNA -5.9% +7.3% -16.4% -0.8% -28.0%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY -5.5% +7.4% -36.6% -0.1% -39.7%

Capital returns

Buyback program · as of Jul 4, 2026
Authorized
$150.00M
Spent (derived)
$116.03M
Remaining
$33.97M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 896264 CUSIP 90328M107 13F (30d) 4 filings 4 filers Visit website Investor relations